Barbara WiÅ›niowska

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4665236/publications.pdf

Version: 2024-02-01

40	546	623734	677142
papers	citations	14 h-index	22 g-index

51	51	51	729
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Open-access database of literature derived drug-related Torsade de Pointes cases. BMC Pharmacology & Toxicology, 2022, 23, 7.	2.4	3
2	Development and Performance Verification of the PBPK Model for Antazoline and Its Metabolite and Its Utilization for Pharmacological Hypotheses Formulating. Pharmaceuticals, 2022, 15, 379.	3.8	1
3	How circadian variability of the heart rate and plasma electrolytes concentration influence the cardiac electrophysiology â€“ model-based case study. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 387-399.	1.8	1
4	Magnetic Coreâ€“Shell Molecularly Imprinted Nano-Conjugates for Extraction of Antazoline and Hydroxyantazoline from Human Plasmaâ€”Material Characterization, Theoretical Analysis and Pharmacokinetics. International Journal of Molecular Sciences, 2021, 22, 3665.	4.1	5
5	Development of physiologically based pharmacokinetic model for the immediate release ropinirole tablets. Acta Poloniae Pharmaceutica, 2021, 78, 317-328.	0.1	0
6	Evolutionary Algorithms in Modeling Aerodynamic Properties of Spray-Dried Microparticulate Systems. Applied Sciences (Switzerland), 2020, 10, 7109.	2.5	0
7	Characterization of In Vitro and In Vivo Metabolism of Antazoline Using Liquid Chromatography-Tandem Mass Spectrometry. International Journal of Molecular Sciences, 2020, 21, 9693.	4.1	2
8	An Open-Access Dataset of Thorough QT Studies Results. Data, 2020, 5, 10.	2.3	4
9	Better prediction of the local concentrationâ€“effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development. Drug Discovery Today, 2019, 24, 1344-1354.	6.4	17
10	Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin. AAPS Journal, 2018, 20, 47.	4.4	10
11	Drugâ€“physiology interaction and its influence on the QT prolongation-mechanistic modeling study. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 483-490.	1.8	0
12	Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram. AAPS Journal, 2018, 20, 6.	4.4	23
13	Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models. Journal of Applied Toxicology, 2018, 38, 450-458.	2.8	7
14	Effect of multiple drugs interacting with the hERG channelâ€”In vitro study. Journal of Pharmacological and Toxicological Methods, 2018, 93, 118.	0.7	0
15	Quantitative Assessment of the Physiological Parameters Influencing QT Interval Response to Medication: Application of Computational Intelligence Tools. Computational and Mathematical Methods in Medicine, 2018, 2018, 1-11.	1.3	2
16	Virtual Thorough QT (TQT) Trialâ€”Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine. AAPS Journal, 2018, 20, 83.	4.4	10
17	Thorough QT (TQT) studies: concordance with torsadogenesis and an evolving cardiac safety testing paradigm. Drug Discovery Today, 2017, 22, 1460-1465.	6.4	4
18	Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity. Drug Discovery Today, 2017, 22, 10-16.	6.4	19

#	Article	IF	Citations
19	Humans Vary, So Cardiac Models Should Account for That Too!. Frontiers in Physiology, 2017, 8, 700.	2.8	4
20	The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation. Current Pharmacology Reports, 2016, 2, 339-344.	3.0	13
21	Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example. Journal of Pharmaceutical Sciences, 2016, 105, 3415-3424.	3.3	15
22	Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations. Current Pharmacology Reports, 2016, 2, 171-177.	3.0	20
23	Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacology & Toxicology, 2016, 17, 12.	2.4	54
24	From Heuristic to Mathematical Modeling of Drugs Dissolution Profiles: Application of Artificial Neural Networks and Genetic Programming. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-9.	1.3	17
25	Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates. AAPS Journal, 2015, 17, 1025-1032.	4.4	22
26	Enhanced QSAR models for drugâ€triggered inhibition of the main cardiac ion currents. Journal of Applied Toxicology, 2015, 35, 1030-1039.	2.8	12
27	How in vitro influences in silico utilized for the prediction of in vivo - pilot study of the drug-induced pro-arrhythmic potency prediction. Folia Medica Cracoviensia, 2015, 55, 5-19.	0.3	1
28	In vitroâ€“in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discovery Today, 2014, 19, 275-281.	6.4	22
29	Computer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challenges. Europace, 2014, 16, 724-735.	1.7	14
30	Slow delayed rectifying potassium current (I_{Ks}) â€“ analysis of the in vitro inhibition data and predictive model development. Journal of Applied Toxicology, 2013, 33, 723-739.	2.8	9
31	Virtual population generator for human cardiomyocytes parameters:in silicodrug cardiotoxicity assessment. Toxicology Mechanisms and Methods, 2012, 22, 31-40.	2.7	27
32	Tox-Database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition. BMC Pharmacology & Toxicology, 2012, 13, 6.	2.4	12
33	Predictive model for Lâ€type channel inhibition: multichannel block in QT prolongation risk assessment. Journal of Applied Toxicology, 2012, 32, 858-866.	2.8	12
34	Evaluation of patientsâ€™ adherence to statins in Poland. Current Medical Research and Opinion, 2011, 27, 99-105.	1.9	9
35	Prediction of the hERG potassium channel inhibition potential with use of artificial neural networks. Applied Soft Computing Journal, 2011, 11, 2611-2617.	7.2	15
36	BDTcomparator: a program for comparing binary classifiers. Bioinformatics, 2011, 27, 3439-3440.	4.1	22

#	Article	IF	Citations
37	The open-access dataset for insilico cardiotoxicity prediction system. Bioinformation, 2011, 6, 244-245.	0.5	8
38	Prediction of the hERG Potassium Channel Inhibition Potential with Use of the Artificial Neural Networks. Advances in Intelligent and Soft Computing, 2010, , 91-99.	0.2	1
39	hERG in vitro interchange factorsâ€"development and verification. Toxicology Mechanisms and Methods, 2009, 19, 278-284.	2.7	22
40	Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. Journal of Applied Toxicology, 2009, 29, 183-206.	2.8	103